Penumbra, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
August 04, 2022 at 04:05 pm EDT
Share
Penumbra, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported sales was USD 208.34 million compared to USD 184.26 million a year ago. Net loss was USD 3.69 million compared to net income of USD 9.23 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to basic earnings per share from continuing operations of USD 0.25 a year ago. Diluted loss per share from continuing operations was USD 0.1 compared to diluted earnings per share from continuing operations of USD 0.25 a year ago.
For the six months, sales was USD 412.24 million compared to USD 353.46 million a year ago. Net loss was USD 3.61 million compared to net income of USD 21.07 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to basic earnings per share from continuing operations of USD 0.58 a year ago. Diluted loss per share from continuing operations was USD 0.1 compared to diluted earnings per share from continuing operations of USD 0.56 a year ago.
Penumbra, Inc. is a healthcare company. The Company designs, develops, manufactures, and markets products and has a portfolio that addresses challenging medical conditions in markets with unmet need. It is focused on developing, manufacturing, and marketing products for use by specialist physicians and healthcare providers to drive improved clinical and health outcomes. It is focused on developing and building its portfolio of products, including its thrombectomy, embolization, access, and immersive healthcare technologies. Common conditions that the Company focuses on Pulmonary Embolism, Deep Vein Thrombosis, Peripheral Arterial Occlusion, Ischemic Stroke, Acute Coronary Syndrome, Clot associated with Arteriovenous Graft or Fistula, Aneurysm, and Hemorrhagic Stroke. The Company sells its products to healthcare providers primarily through its direct sales organization in the United States, Europe, Canada and Australia, as well as through distributors in select international markets.